| P2093 | author name string | D Stock | |
| | Y F Gong | |
| | R J Colonno | |
| | P F Lin | |
| | B S Robinson | |
| | R E Rose | |
| | C Deminie | |
| | T P Spicer | |
| P2860 | cites work | ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans | Q27729982 |
| | Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase | Q28325776 |
| | In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease | Q28367941 |
| | Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor | Q28368263 |
| | In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor | Q28368369 |
| | Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor | Q28368832 |
| | Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. | Q28369030 |
| | L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor | Q28369664 |
| | Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors | Q28378853 |
| | Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 |
| | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites | Q28379086 |
| | Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease | Q28379166 |
| | Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor | Q28379356 |
| | A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A | Q28379487 |
| | In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors | Q29620622 |
| | Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. | Q33539266 |
| | Advances in the medical management of patients with HIV-1 infection: an overview | Q33765167 |
| | Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy | Q33784635 |
| | A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 |
| | Resistance to human immunodeficiency virus type 1 protease inhibitors. | Q39559316 |
| | Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | Q39580564 |
| | Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors | Q39582620 |
| | Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors | Q39780160 |
| | The retroviral enzymes | Q40394916 |
| | Current knowledge and future prospects for the use of HIV protease inhibitors | Q40940050 |
| | Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. | Q41381139 |
| | Human immunodeficiency virus type 1 protease inhibitors | Q41461737 |
| | HIV-protease inhibitors | Q41751665 |
| | Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959 | Q42276433 |
| | Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy | Q42282495 |
| | Ordered accumulation of mutations in HIV protease confers resistance to ritonavir | Q42555782 |
| | The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. | Q42630241 |
| | Current antiretroviral therapy: an overview | Q44022777 |
| | Ritonavir and saquinavir combination therapy for the treatment of HIV infection | Q44174531 |
| | New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity | Q45033160 |
| | A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection | Q45755838 |
| | In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies | Q45770453 |
| | Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). | Q48061498 |
| | Recent developments in HIV protease inhibitor therapy | Q77354774 |
| | HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy | Q77386253 |
| | Antiretroviral therapies in HIV-1 infection | Q94447136 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2319-26 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 | |
| P478 | volume | 44 | |